Monopar Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference

Monopar Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference

September 05, 2023 | Last Trade: US$24.34 0.19 -0.77

WILMETTE, Ill., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer patients, today announced that Chandler D. Robinson, MD, Monopar’s Chief Executive Officer, will present at the H.C. Wainwright 25^th Annual Global Investment Conference. The Company’s presentation will be webcast beginning on Monday, September 11, 2023 at 7:00 a.m. ET. In person one-on-one meetings will take place at the Lotte New York Palace, NY, NY from September 11 - 13, 2023.

About Monopar Therapeutics Inc.

Monopar Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer patients. Monopar's pipeline consists of camsirubicin (Phase 1b) for the treatment of advanced soft tissue sarcoma; MNPR-101, a late-stage preclinical antibody for radiopharmaceutical use in advanced cancers; and MNPR-202, an early-stage camsirubicin analog for various cancers. For more information, visit: www.monopartx.com.

CONTACT:

Monopar Therapeutics Inc.
Investor Relations
Kim R. Tsuchimoto
Chief Financial Officer
This email address is being protected from spambots. You need JavaScript enabled to view it.

Follow Monopar on social media for updates:
Twitter: @MonoparTx LinkedIn: Monopar Therapeutics

Stock Quote

Last Trade:	US$24.34
Daily Change:	-0.19 -0.77
Daily Volume:	37,544
Market Cap:	US$128.520M

December 05, 2024 Monopar Therapeutics Announces First Patient Dosed with its Novel Therapeutic Radiopharmaceutical MNPR-101-Lu December 03, 2024 Monopar Therapeutics to Present at the 36th Annual Piper Sandler Healthcare Conference November 08, 2024 Monopar Therapeutics Reports Third Quarter 2024 Financial Results and Recent Developments October 28, 2024 Monopar Therapeutics Announces Proposed Public Offering of Common Stock October 24, 2024 Monopar Therapeutics Announces Agreement with Alexion, AstraZeneca Rare Disease For Late-Stage Wilson Disease Drug Candidate LOAD MORE NEWS

Featured Stock

ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...

CLICK TO LEARN MORE

Featured Stock

Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...

CLICK TO LEARN MORE